Company profile: OncoPep
1.1 - Company Overview
Company description
- Provider of investigational multi-peptide therapeutic cancer vaccines and adoptive T cell therapies, including PVX-410 for patients with triple negative breast cancer (TNBC) and asymptomatic multiple myeloma (MM)/smoldering multiple myeloma (SMM); MTAA-420 for multiple myeloma; and second-generation vaccines PVX-024/PVX-510 to enhance the first iteration of OncoPep's vaccine and expand to additional HLA subtypes, such as HLA-A24.
Products and services
- MTAA-420: Autologous adoptive T cell therapy targeting multiple tumor antigens, initially developed for the treatment of multiple myeloma (MM)
- PVX-024/PVX-510: Second-generation vaccines currently being explored to enhance the first iteration of OncoPep's vaccine and expand it to additional HLA subtypes, such as HLA-A24
- PVX-410: Investigational multi-peptide therapeutic cancer vaccine engineered to prevent progression, developed for patients with triple negative breast cancer (TNBC) and asymptomatic multiple myeloma (MM)/smoldering multiple myeloma (SMM)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OncoPep
Apexigen
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology antibody therapeutics for cancer, including sotigalimab (PYX-107), a Phase 2 CD40 agonist with demonstrated anti-cancer activity in patients who have progressed on PD-(L)1 inhibitors, and the APXiMAB platform for generating novel antibodies optimized for targeted payload delivery in antibody-drug conjugates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apexigen company profile →
Tiziana Life Sciences
HQ: United Kingdom
Website
- Description: Provider of biotechnology therapies focused on discovery and development of novel molecules in oncology and immunology, including Intranasal Foralumab (anti-CD3 nasal immunotherapy for neuroinflammatory and neurodegenerative diseases), Anti IL-6R mAb (TZLS-501) to reduce inflammation in idiopathic pulmonary fibrosis and autoimmune diseases, and Milciclib, a CDK-targeting cancer therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tiziana Life Sciences company profile →
Xenikos
HQ: The Netherlands
Website
- Description: Provider of antibody-based immunotherapies, developing a combination of two toxin-loaded anti-T-cell antibodies to quickly reset the immune system in patients with serious immune diseases or transplant rejection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xenikos company profile →
Arcellx
HQ: United States
Website
- Description: Provider of immune cell therapies, including anitocabtagene autoleucel, a CAR-T targeting BCMA for relapsed or refractory multiple myeloma (Phase 1); ACLX-001, a controllable ARC-T cell therapy with a bivalent SparX protein targeting BCMA for relapsed or refractory multiple myeloma; and ACLX-002, an ARC-SparX therapy targeting CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcellx company profile →
NovAccess Global
HQ: United States
Website
- Description: Provider of cancer and neurological disease immunotherapies and diagnostics, combining clinical-stage asset acquisition with medical assets in the market. Through StemVax Therapeutics, develops dendritic cell-based immunotherapies for glioblastoma with TLR adjuvants, and leverages AI, bio-sensing, and blockchain-powered AI to advance diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovAccess Global company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OncoPep
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OncoPep
2.2 - Growth funds investing in similar companies to OncoPep
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OncoPep
4.2 - Public trading comparable groups for OncoPep
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →